Intelligent Bio Solutions Inc. (Nasdaq: INBS) announces fiscal fourth quarter and full-year results for 2025.
The company achieved sequential and year-on-year revenue growth of 16%, driven by increased demand for drug testing cartridges.
Focus on securing FDA 510(k) clearance to expand into the U.S. drug screening market.
Revenue Growth
16% revenue growth supported by increased demand for drug testing cartridges.
FDA Clearance Progress
Focused on securing FDA 510(k) clearance for opiate test system for codeine in the U.S.
Market Expansion
Expanding commercial presence internationally with over 450 active customer accounts across 24 countries.
- Intelligent Bio Solutions achieved strong revenue growth in fiscal Q4, driven by high-margin cartridge sales and strategic partnerships.
- Progress towards FDA clearance and U.S. market expansion positions the company for future growth opportunities.
- Operational efficiencies and localization efforts strengthen the company's fundamentals for sustained growth.
With a focus on growth, operational excellence, and regulatory advancements, Intelligent Bio Solutions is poised for expansion beyond current market settings. The company's commitment to non-invasive testing solutions sets a solid foundation for future success.